Stratos Wealth Partners LTD. Boosts Stock Position in Eli Lilly and Company (NYSE:LLY)

Stratos Wealth Partners LTD. grew its holdings in Eli Lilly and Company (NYSE:LLY) by 1.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,622 shares of the company’s stock after purchasing an additional 415 shares during the period. Stratos Wealth Partners LTD.’s holdings in Eli Lilly and Company were worth $31,560,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. OmniStar Financial Group Inc. boosted its position in Eli Lilly and Company by 154.9% in the 3rd quarter. OmniStar Financial Group Inc. now owns 678 shares of the company’s stock valued at $602,000 after buying an additional 412 shares during the period. Trust Point Inc. raised its stake in shares of Eli Lilly and Company by 7.7% during the third quarter. Trust Point Inc. now owns 4,050 shares of the company’s stock valued at $3,588,000 after acquiring an additional 290 shares in the last quarter. Aaron Wealth Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 14.6% in the third quarter. Aaron Wealth Advisors LLC now owns 5,404 shares of the company’s stock valued at $4,788,000 after purchasing an additional 690 shares during the period. Stonegate Investment Group LLC grew its stake in Eli Lilly and Company by 1.5% in the third quarter. Stonegate Investment Group LLC now owns 56,999 shares of the company’s stock worth $50,498,000 after purchasing an additional 862 shares in the last quarter. Finally, Claro Advisors LLC raised its position in Eli Lilly and Company by 19.0% during the 3rd quarter. Claro Advisors LLC now owns 4,556 shares of the company’s stock valued at $4,036,000 after purchasing an additional 726 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 0.1 %

NYSE:LLY opened at $917.86 on Friday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The company’s fifty day moving average price is $921.21 and its 200-day moving average price is $857.37. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53. The firm has a market capitalization of $872.34 billion, a P/E ratio of 135.18, a PEG ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, equities research analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on LLY. Morgan Stanley restated an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Finally, Bank of America upped their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $986.00.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.